Skip to main content
Top
Published in: International Journal of Clinical Oncology 6/2022

01-06-2022 | Ovarian Cancer | Original Article

Recent trends in the morbidity and mortality in patients with familial adenomatous polyposis: a retrospective single institutional study in Japan

Authors: Yoshiko Mori, Kunihiko Amano, Kenichi Chikatani, Tetsuya Ito, Okihide Suzuki, Nao Kamae, Satoshi Hatano, Noriyasu Chika, Azusa Yamamoto, Keiichiro Ishibashi, Hidetaka Eguchi, Yasushi Okazaki, Takeo Iwama, Hideyuki Ishida

Published in: International Journal of Clinical Oncology | Issue 6/2022

Login to get access

Abstract

Background

This study aimed to assess current trends in morbidity and mortality among patients with familial adenomatous polyposis (FAP). These data can be used for optimal surveillance and management of such patients.

Methods

Data (November 2001 and April 2020) of genetically confirmed patients with FAP (n = 87) and their first-degree relatives with FAP phenotype (n = 20) were extracted from the Saitama Medical Center database. Standardized mortality ratio (SMR) and standardized incidence ratio (SIR) were estimated using indirect method.

Results

Overall, 46 men and 61 women were included; the median age at FAP diagnosis was 28.0 years for both. The SMR for all causes of death was 47.7 (95% confidence interval [CI] 19.1–98.2) in women and 26.5 (95% CI 9.73–57.8) in men. The SIR for colorectal cancer (CRC) was 860 (95% CI 518–1340) in women and 357 (95% CI 178–639) in men. The SMR for CRC was 455 (95% CI 93.7–1330) in women and 301 (95% CI 62.0–879) in men. Thirteen patients died during the observation period, and CRC was the leading cause of death (46%). Other causes of death included desmoid tumor (n = 2), small intestinal cancer (n = 2), ovarian cancer (n = 1), duodenal cancer (n = 1), and sepsis (n = 1).

Conclusions

The mortality ratio, estimated using SMR, remained high. CRC was the leading cause of death, whereas almost half of the causes of deaths were extra-colonic tumors. Life-long management of extra-colonic diseases may improve the prognosis in these patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Komatsu I (1968) A clinical genetic study on multiple intestinal polyposis and allied conditions. Jinrui Idengaku Zasshi 12:246–297PubMed Komatsu I (1968) A clinical genetic study on multiple intestinal polyposis and allied conditions. Jinrui Idengaku Zasshi 12:246–297PubMed
2.
go back to reference Utsunomiya J, Iwama T, Ichikawa T et al (1973) Present status of familial polyposis of the colon in Japan-results of the nationwide survey (1961–1972). Nihon Shokakibyo Gakkai Zasshi 70:707–726PubMed Utsunomiya J, Iwama T, Ichikawa T et al (1973) Present status of familial polyposis of the colon in Japan-results of the nationwide survey (1961–1972). Nihon Shokakibyo Gakkai Zasshi 70:707–726PubMed
3.
go back to reference Iwama T, Tamura K, Morita T et al (2004) A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan. Int J Clin Oncol 9:308–316CrossRef Iwama T, Tamura K, Morita T et al (2004) A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan. Int J Clin Oncol 9:308–316CrossRef
4.
go back to reference Weren RD, Ligtenberg MJ, Kets CM et al (2015) A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet 47:668–671CrossRef Weren RD, Ligtenberg MJ, Kets CM et al (2015) A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet 47:668–671CrossRef
5.
go back to reference Short E, Sampson J (2019) The role of inherited genetic variants in colorectal polyposis syndromes. Adv Genet 103:183–217CrossRef Short E, Sampson J (2019) The role of inherited genetic variants in colorectal polyposis syndromes. Adv Genet 103:183–217CrossRef
6.
go back to reference Carr S, Kasi A (2020) Familial adenomatous polyposis. Treasure Island (FL), StatPearls Publishing LLC, StatPearls Carr S, Kasi A (2020) Familial adenomatous polyposis. Treasure Island (FL), StatPearls Publishing LLC, StatPearls
7.
go back to reference Jasperson KW, Patel SG, Ahnen DJ (1993) APC-Associated polyposis conditions, in GeneReviews(®). Seattle, USA Jasperson KW, Patel SG, Ahnen DJ (1993) APC-Associated polyposis conditions, in GeneReviews(®). Seattle, USA
8.
go back to reference Utsunomiya J, Iwama T, Imajo M et al (1980) Total colectomy, mucosal proctectomy, and ileoanal anastomosis. Dis Colon Rectum 23:459–466CrossRef Utsunomiya J, Iwama T, Imajo M et al (1980) Total colectomy, mucosal proctectomy, and ileoanal anastomosis. Dis Colon Rectum 23:459–466CrossRef
9.
go back to reference Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. IARC Sci Publ 82:1–406 Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. IARC Sci Publ 82:1–406
13.
go back to reference Schoenberg BS (1983) Caluculating confidence intervals for rates and ratios- Simplified method utilizing tabular values based on the poisson distribution. Neuroepidemiology 2:257–265CrossRef Schoenberg BS (1983) Caluculating confidence intervals for rates and ratios- Simplified method utilizing tabular values based on the poisson distribution. Neuroepidemiology 2:257–265CrossRef
14.
go back to reference Iwama T, Mishima Y, Utsunomiya J (1993) The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 217:101–108CrossRef Iwama T, Mishima Y, Utsunomiya J (1993) The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 217:101–108CrossRef
15.
go back to reference Galle TS, Juel K, Bülow S (1999) Causes of death in familial adenomatous polyposis. Scand J Gastroenterol 34:808–812CrossRef Galle TS, Juel K, Bülow S (1999) Causes of death in familial adenomatous polyposis. Scand J Gastroenterol 34:808–812CrossRef
16.
go back to reference Bülow S (2003) Results of national registration of familial adenomatous polyposis. Gut 52:742–746CrossRef Bülow S (2003) Results of national registration of familial adenomatous polyposis. Gut 52:742–746CrossRef
18.
go back to reference Chugh R, Wathen JK, Patel SR et al (2010) Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 16:4884–4891CrossRef Chugh R, Wathen JK, Patel SR et al (2010) Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 16:4884–4891CrossRef
19.
go back to reference Mir O, Cropet C, Toulmonde M et al (2016) Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 17:632–641CrossRef Mir O, Cropet C, Toulmonde M et al (2016) Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 17:632–641CrossRef
20.
go back to reference Penel N, Le Cesne A, Bui BN et al (2011) Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 22:452–457CrossRef Penel N, Le Cesne A, Bui BN et al (2011) Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 22:452–457CrossRef
21.
go back to reference Kasper B, Gruenwald V, Reichardt P et al (2017) Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer 76:60–67CrossRef Kasper B, Gruenwald V, Reichardt P et al (2017) Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer 76:60–67CrossRef
22.
go back to reference Jo JC, Hong YS, Kim KP et al (2014) A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs 32:369–376CrossRef Jo JC, Hong YS, Kim KP et al (2014) A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs 32:369–376CrossRef
23.
go back to reference Gounder MM, Mahoney MR, Van Tine BA et al (2018) Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 379:2417–2428CrossRef Gounder MM, Mahoney MR, Van Tine BA et al (2018) Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 379:2417–2428CrossRef
24.
go back to reference Watanabe Y, Ishida H, Baba H et al (2017) Pancreas-sparing total duodenectomy for Spigelman stage IV duodenal polyposis associated with familial adenomatous polyposis: experience of 10 cases at a single institution. Fam Cancer 16:91–98CrossRef Watanabe Y, Ishida H, Baba H et al (2017) Pancreas-sparing total duodenectomy for Spigelman stage IV duodenal polyposis associated with familial adenomatous polyposis: experience of 10 cases at a single institution. Fam Cancer 16:91–98CrossRef
25.
go back to reference Kumagai Y, Higashi M, Muramatsu S et al (2020) Endocytoscopic observation of non-ampullary mucosal duodenal cancer. Case Rep Gastroenterol 14:156–164CrossRef Kumagai Y, Higashi M, Muramatsu S et al (2020) Endocytoscopic observation of non-ampullary mucosal duodenal cancer. Case Rep Gastroenterol 14:156–164CrossRef
26.
go back to reference Yamaguchi T, Ishida H, Ueno H et al (2016) Upper gastrointestinal tumours in Japanese familial adenomatous polyposis patients. Jpn J Clin Oncol 46:310–315CrossRef Yamaguchi T, Ishida H, Ueno H et al (2016) Upper gastrointestinal tumours in Japanese familial adenomatous polyposis patients. Jpn J Clin Oncol 46:310–315CrossRef
27.
go back to reference Sada H, Hinoi T, Ueno H et al (2019) Prevalence of and risk factors for thyroid carcinoma in patients with familial adenomatous polyposis: results of a multicenter study in Japan and a systematic review. Surg Today 49:72–81CrossRef Sada H, Hinoi T, Ueno H et al (2019) Prevalence of and risk factors for thyroid carcinoma in patients with familial adenomatous polyposis: results of a multicenter study in Japan and a systematic review. Surg Today 49:72–81CrossRef
28.
go back to reference Yamada A, Watabe H, Iwama T et al (2014) The prevalence of small intestinal polyps in patients with familial adenomatous polyposis: a prospective capsule endoscopy study. Fam Cancer 13:23–28CrossRef Yamada A, Watabe H, Iwama T et al (2014) The prevalence of small intestinal polyps in patients with familial adenomatous polyposis: a prospective capsule endoscopy study. Fam Cancer 13:23–28CrossRef
29.
go back to reference Nugent KP, Spigelman AD, Phillips RK (1993) Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum 36:1059–1062CrossRef Nugent KP, Spigelman AD, Phillips RK (1993) Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum 36:1059–1062CrossRef
Metadata
Title
Recent trends in the morbidity and mortality in patients with familial adenomatous polyposis: a retrospective single institutional study in Japan
Authors
Yoshiko Mori
Kunihiko Amano
Kenichi Chikatani
Tetsuya Ito
Okihide Suzuki
Nao Kamae
Satoshi Hatano
Noriyasu Chika
Azusa Yamamoto
Keiichiro Ishibashi
Hidetaka Eguchi
Yasushi Okazaki
Takeo Iwama
Hideyuki Ishida
Publication date
01-06-2022
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology / Issue 6/2022
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-022-02146-4

Other articles of this Issue 6/2022

International Journal of Clinical Oncology 6/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine